Eye implant for diabetes? trial pulled before it began
NCT ID NCT04198350
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study aimed to transplant insulin-producing cells into the front chamber of the eye for people with type 1 diabetes and poor vision. The goal was to see if the procedure was safe for the eye. However, the trial was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pancreatic islet cells
- What this could lead to
- If successful, this could offer a new site for islet transplantation, potentially improving diabetes control while preserving vision.
- What could go wrong
- The trial was withdrawn before any participants enrolled, so no data exists. The procedure requires lifelong immunosuppression, which carries serious risks. Vision complications are a major concern.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Imperial College London, Imperial College Healthcare NHS Trust
London, W2 1PG, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an app and cash rewards tame type 1 diabetes in young adults?
- Smart insulin pump aims to end dangerous nighttime blood sugar swings
- Could diabetes be silently damaging your hearing?
- Hidden liver risk in type 1 diabetes: a new study investigates
- App aims to shield visually impaired youth from social media's body image pitfalls
- Can a wearable sensor outsmart diabetic ketoacidosis?